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Abstract The synthesis of triaryl methanols was investigated by react-
ing different 4-metalated 2-substituted pyrimidines with diaryl ketones,
the latter being generated by deprotocupration–aroylation of azine and
diazine substrates. Cyclization of the triaryl methanols thus obtained af-
forded pyrido[3′,2′:4,5]pyrrolo[1,2-c]pyrimidines, which were evaluat-
ed for kinase inhibition and antiproliferative activities in melanoma
cells.
Key words diaryl ketone, pyrimidine, deprotometalation, mixed-metal
amide, variolin analogue
Variolins are a family of marine alkaloids isolated from
the Antartic sponge Kirkpatrickia varialosa.1 Among them,
variolin B is a tricyclic system bearing a substituent at the
5-position endowed with biological properties such as anti-
tumor and antiviral.1a,2 Several total syntheses of variolin
B and analogues have been reported.2b,3 In the convergent
synthesis of Morris,3b,3h,4 the key step involves the tandem
deoxygenation–cyclization of a triaryl methanol, the latter
being for example obtained by reaction of 2-chloro-3-
lithio-4-methoxypyridine on a symmetrical ketone
(Scheme 1).
Scheme 1  Morris synthesis of variolin B
Because of our interest in the synthesis of diaryl ketones
by deprotocupration–aroylation,5 we decided to evaluate
the reactivity of these ketones toward different 4-metalated
2-substituted pyrimidines in order to reach different triaryl
methanols. Thus, the required diaryl ketones were prepared
from azines or diazines as reported previously.5 The latter
were deprotocuprated at room temperature in tetrahydro-
furan (THF) containing N,N,N′,N′-tetramethylethylenedi-
amine (TMEDA) by using (TMP)2CuLi·LiCl (TMP = 2,2,6,6-tet-
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N. Marquise et al. ClusterSyn lettramethylpiperidino), prepared in situ from CuCl and LiTMP
(2 equiv). Trapping with aroyl chlorides after two hours fur-
nished the compounds 1a–i (Scheme 2).
Scheme 2  Synthesis of the diaryl ketones 1a–i
We next considered the formation of 4-metalated
2-chloropyrimidine from 2 and its trapping. The pyrimi-
dine 2 being prone to nucleophilic attacks,6 we first tried to
use the base prepared in situ by mixing ZnCl2·TMEDA
and LiTMP in a 1:3 ratio,7 and supposed to be a 1:1
LiTMP·2LiCl(±TMEDA)–Zn(TMP)2 mixture.8 It proved not
appropriate, with the iodide 4a isolated in a low 18% yield
when the deprotonation step was performed at 0 °C
and only degradation noticed at higher temperatures.
TMPMgCl·LiCl being a suitable base for 2 in THF at –60 °C,
as evidenced by subsequent iodolysis after two hours,9 we
thus employed it in order to attempt the interception of the
deprotomagnesated species with the ketone 1a. The ex-
pected triaryl methanol 4b was obtained in a moderate 33%
yield by carrying out the reaction at –60 °C, but its forma-
tion could be improved with a deprotonation step at –40 °C
(Scheme 3).
4-Metalated derivatives of 2-(methylthio)pyrimidine (3)
could be formed at room temperature in THF by using ei-
ther the previous lithium–zinc base or the corresponding
lithium–cadmium base, prepared in situ by mixing
CdCl2·TMEDA (0.5 equiv) and LiTMP (1.5 equiv).10 This was
evidenced by iodolysis to afford 5a in correct yields. When
TMPMgCl·LiCl was employed at –60 °C, the alcohol 5b re-
sulting from a quenching with the ketone 1a was obtained
in a moderate 21% yield (Scheme 4).
To reach the triaryl methanols, it also proved possible to
involve the iodide 5a in a butyllithium-mediated halogen–
metal exchange reaction in the presence of the ketone 1a or
1b. Performing this reaction in THF at –95 °C, as previously
documented by Morris,3b,h,4 led to the alcohol 5b or 6b in
72% or 45% yield, respectively. Replacing methanol quench-
ing with acetyl chloride afforded the corresponding acetate
5b′. Finally, treating both 5b and 5b′ with triethylsilane and
trifluoroacetic acid at 100 °C in 1,2-dichloroethane fur-
nished the phenyl-substituted tricycle 7b in 45% yield
(Scheme 5). Because no improvement was here noted by
using the acetate 5b′ as intermediate,4 we kept the se-
quence involving triaryl methanols for the rest of the study.
In order to prepare analogues of 9-(methylthio)-5-
phenylpyrido[3′,2′;4,5]pyrrolo[1,2-c]pyrimidine (7b), we
aimed at synthesizing various triaryl methanols (Table 1).
When 2-chloro-4-iodopyrimidine (4a) was involved instead
of 5a in the reaction with 1a, a lower 24% yield was noticed
(Table 1, entries 1 and 2). With the other aryl(2-chloro-3-
pyridyl)methanones 1c–e, the expected alcohols were iso-
lated in yields ranging from 52–70% (Table 1, entries 3–5).
The position of chlorine on the (2-chloro-3-pyridyl)(chloro-
3-pyridyl)methanone is an important parameter for the
success of the reaction. Indeed, whereas a good 75% yield
was registered by using 1f (compound 5f, Table 1, entry 6),
a complex mixture without the expected derivative togeth-
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try 7). With the ketones 1h and 1i bearing a pyrimidyl
group, things become difficult, probably in relation with
ring sensitivity to nucleophilic attacks; as a consequence,
the alcohol 5i was the only to be formed, in a very low 8%
yield (Table 1, entries 8 and 9).
Table 1  Synthesis of the Triaryl Methanols 4b and 5b–i
Entry Substrate X 1 Product Yield (%)
1 4a Cl 1a
4b
24
2 5a SMe 1a
5b
72
3 5a SMe 1c
5c
70
Scheme 5  Synthesis of 9-(methylthio)-5-phenylpyrido[3′,2′:4,5]pyrro-
lo[1,2-c]pyrimidine (7b)
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In order to progress toward the corresponding 5-aryl
tricycles, the triaryl methanols were submitted to the ac-
tion of triethylsilane and trifluoroacetic acid as before (Ta-
ble 2). Under these conditions, the targets 7b–f were gener-
ated in moderate yields (Table 2, entries 2–6). No cycliza-
tion was noticed from the dichloride 4b (Table 2, entry 1).
Similarly, cyclization of the dichloride 6b did not take place
under the conditions used (Table 2, entry 7). In both cases,
starting material was recovered.
4 5a SMe 1d
5d
59
5 5a SMe 1e
5e
52
6 5a SMe 1f
5f
75
7 5a SMe 1g
5g
 0
8 5a SMe 1h
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 0
9 5a SMe 1i
5i
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N. Marquise et al. ClusterSyn lettTable 2  Synthesis of the Tricycles 7b–f Variolin B was characterized as a potent inhibitor of cy-
clin-dependent kinases (CDK), key actors involved notably
in the regulation of the cell-division cycle, programmed
cell-death by apoptosis, transcription as well as differentia-
tion.2a This chemical scaffold was consequently used to de-
sign new inhibitors of CDK.11 In this study we thus tested
the new derivatives on a panel of nine protein kinases in-
cluding CDK5: HsAurora B, HsCDK5/p25, HsRIPK3 (receptor
interacting protein kinase), HsHaspin; porcine (Sus scrofa)
SsGSK-3 (glycogen synthase kinase-3) and SsCK1 (casein ki-
nase 1); kinases from the protozoan parasites, Leishmania
major LmCK1, Plasmodium falciparum PfGSK-3, and from
Leishmania donovani LdTLK (tousled-like kinase). These ki-
nases were not significantly affected by the tested chemical
compounds (5b–e and 7c–f) with none of the molecules
causing more than 50% inhibition of enzymatic activity at
10–5 M.
The antiproliferative activity of the 5,9-disubstituted
pyrido[3′,2′:4,5]pyrrolo[1,2-c]pyrimidines 5b–e and 7c–f
was studied in the A2058 (ATCC® CRL-11147) melanoma
cell line (Figure 1). A2058 are highly invasive human epi-
thelial adherent melanoma cells, derived from lymph nodes
metastatic cells obtained from a 43 years male patient.
They are tumorigenic at 100% frequency in nude mice and
considered as very resistant to anticancer drugs.
The compounds 5 exerted low antiproliferative activity
in A2058 melanoma cells, with 0–13% growth inhibition in
cells treated for 72 h at 10–5 M. In contrast, the compounds
7 exhibited 23–44% growth inhibition and were considered
as moderately antiproliferative. This activity was not cor-
related to CDK inhibition, as all molecules were inactive at
10–5 M in the CDK inhibition assay. Because of the presence
of the sp3 carbon, the compounds 5 are not planar in con-
trast to the compounds 7. This observation indicates that
the planar structure improves the antiproliferative activity
and suggests that the cytotoxicity of these new compounds
may be related to a DNA intercalating activity, as previously
reported with variolin analogues.1a,b The nature of the ring
Entry Substrate X, R Product Yield (%)
1 4b Cl, H
7a
 0a
2 5b SMe, H
7b
45
3 5c SMe, H
7c
23
4 5d SMe, H
7d
36
5 5e SMe, H
7e
18
6 5f SMe, H
7f
21
7 6b SMe, Cl
7g
0a
a Only starting material was recovered.
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N. Marquise et al. ClusterSyn lettconnected to the tricycle also plays an important role, as the
absence of cycle leads to a complete loss of activity, as ob-
served with variolin D.1c Moreover, the presence of ring ni-
trogens or/and amino function is also critical for CDK inhi-
bition.2a
As a conclusion, 2-substituted pyrimidines could be
functionalized at their 4-position by using a lithium–metal
TMP-based deprotonating agent.12–14 The triaryl methanols
obtained either after subsequent quenching, or through io-
dine–lithium exchange with in situ ketone trap, were cy-
clized to afford new pyrido[3′,2′:4,5]pyrrolo[1,2-c]pyrimi-
dines.
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